Frost and Sullivan, USA
Scientific Tracks Abstracts: J Bioanal Biomed
The global life sciences industry is witnessing a surge in Chief Executive Officer (CEO) confidence from US tax reforms, turbulent equity markets, and the strengthening global economy. The growth of the life sciences industry is boosted by healthcare digitization and democratization creating an explosion in patient data, the emergence of value based reimbursement models, and healthcare consumerism shifting the risk from payers to providers. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics enabled by digital connectivity is driving regulatory and commercial changes in many exciting ways for the industry. In this session hear about Frost and SullivanÔ??s perspective of how business models are changing to maximize growth in life science companies as they embrace the new trends and technology. Key takeaways include top 3 growth opportunities in the biopharmaceutical industry, perspectives from game changing companies on collaborative projects, impact on disruptive technology platforms and best practices for implementing new business models.
Nitin Naik leads the global life sciences practice at Frost and Sullivan and is responsible for aligning cross-functional initiatives to achieve focused business results. He plays a pivotal role in helping life science companies realize their audacious goal of unhinging the most transformative pivots in the precision medicine landscape. He has more than 20years of healthcare industry expertise, including 15 plus years of consulting expertise focusing on the pharmaceutical and biotechnology sector. He works closely with Frost and Sullivan’s leadership and sales teams to expand research services and brand and demand solution footprint. Prior to his current role, he worked with GE Healthcare (national distributor), Frost and Sullivan Asia and A*STAR Singapore in various roles from strategy, marketing to inlicensing, portfolio management, and market planning. His experience and expertise have made him a go-to expert for commentary about emerging industry trends. He studied Biomedical Engineering (Gold Medalist) at Bombay University. He has an MBA (International Business) from S.P. Jain Institute of Management and Research (SPJIMR), India and pursued Advanced Management Program (Corporate Strategy and Finance) from Stanford-NUS.
E-mail: [email protected]
Journal of Bioanalysis & Biomedicine received 2511 citations as per Google Scholar report